Response to induction chemotherapy
| . | Standard group, n = 93 . | VPA group, n = 93 . | P . |
|---|---|---|---|
| After the first induction cycle | |||
| CR, n (%) | 32 (34.4) | 29 (31.2) | .75 |
| Cri, n (%) | 10 (10.8) | 7 (7.5) | |
| PR, n (%) | 7 (7.5) | 8 (8.6) | |
| RD, n (%) | 31 (33.3) | 31 (33.3) | .99 |
| Death, n (%) | 13 (13.9) | 18 (19.4) | .43 |
| After 2 induction cycles | |||
| CR, n (%) | 48 (51.6) | 37 (39.8) | .14 |
| RD, n (%) | 32 (34.4) | 32 (34.4) | .99 |
| Death, n (%) | 13 (13.9) | 24 (25.8) | .06 |
| . | Standard group, n = 93 . | VPA group, n = 93 . | P . |
|---|---|---|---|
| After the first induction cycle | |||
| CR, n (%) | 32 (34.4) | 29 (31.2) | .75 |
| Cri, n (%) | 10 (10.8) | 7 (7.5) | |
| PR, n (%) | 7 (7.5) | 8 (8.6) | |
| RD, n (%) | 31 (33.3) | 31 (33.3) | .99 |
| Death, n (%) | 13 (13.9) | 18 (19.4) | .43 |
| After 2 induction cycles | |||
| CR, n (%) | 48 (51.6) | 37 (39.8) | .14 |
| RD, n (%) | 32 (34.4) | 32 (34.4) | .99 |
| Death, n (%) | 13 (13.9) | 24 (25.8) | .06 |